VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Updates from the ADVANCE study

Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some updates from the ADVANCE study (NCT03290950), which is comparing the combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed myeloma. This study is also evaluating measurable residual disease (MRD) negativity as the primary endpoint. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter